ProlyteORS, the flagship brand of Cipla Health Limited, welcomes the recent directive from the Food Safety and Standards ...

Eli Lilly signed an agreement with Cipla , allowing the Indian drugmaker to sell its blockbuster weight-loss drug under a ...

Eli Lilly ( NYSE: LLY) has partnered with India's Cipla to market its weight-loss medication Tirzepatide under a new brand in ...

Stay up-to-date with the Cipla Stock Liveblog, your trusted source for real-time updates and thorough analysis of a prominent ...

Cipla Health, one of India’s leading consumer healthcare companies, has entered the sexual wellness category with the launch ...

The collaboration aims to create a brand that moves away from traditional category norms while focusing on openness, trust, ...

Analysts say that while the deal is a positive for the stock, it has already been priced in and investors are now resorting ...

Eli Lilly and Cipla have joined forces. Cipla will now market Lilly's popular weight-loss drug in India. The medication will ...

Cipla will market Eli Lilly’s diabetes and weight-loss drug Mounjaro as Yurpeak in India, enhancing accessibility and ...

Analysts believe that while the deal is positive, Cipla's share price is unlikely to see a fresh run-up, given the rise it ...

Cipla enters obesity and diabetes drug market with Eli Lilly's tirzepatide 'Yurpeak'; Nuvama retains 'Hold' on Cipla stock, ...

Cipla collaboration brings a second brand of tirzepatide, Yurpeak, to India, aiming to widen patient access for diabetes and ...